Literature DB >> 6322396

Pituitary adenomas producing growth hormone, prolactin, and one or more glycoprotein hormones: a histologic, immunohistochemical, and ultrastructural study of four surgically removed tumors.

E Horvath, K Kovacs, B W Scheithauer, R V Randall, E R Laws, M O Thorner, G T Tindall, D L Barrow.   

Abstract

The morphologic features of four pituitary adenomas, removed from 2 men and 2 women between 31 and 62 years of age, are reported. The tumors contained growth hormone (GH), prolactin (PRL), and one or more glycoprotein hormones--usually thyrotropin (TSH). Three tumors were associated with acromegaly and one with hyperprolactinemia. Hyperthyroidism was not evident in any of the patients. In the tumors of acromegalic subjects, GH-containing cells were the most numerous, whereas PRL cells were dominant in the adenoma accompanied by hyperprolactinemia. Electron microscopy revealed plurimorphous tumors comprised of various proportions of morphologically different cell types: densely granulated GH cells, TSH-like cells, and the less common mammosomatotrophs and PRL cells. It is suggested that pituitary adenomas producing GH, PRL, and glycoprotein hormones derive from the same precursor; their immunocytochemical profile, fine structural appearance, and endocrine function may depend on the degree and direction of the cellular differentiation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6322396     DOI: 10.3109/01913128309141837

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  11 in total

1.  Stress-response proteins in human pituitary adenomas. Expression of heat-shock protein 72 (HSP-72).

Authors:  G Kontogeorgos; L Stefaneanu; K Kovacs
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

Review 2.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

Review 3.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

4.  Immunohistochemical colocalization of growth hormone (GH) and alpha subunit in human GH secreting pituitary adenomas.

Authors:  R Y Osamura; K Watanabe
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

5.  Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization.

Authors:  K Kovacs; R Lloyd; E Horvath; S L Asa; L Stefaneanu; D W Killinger; H S Smyth
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

6.  Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary. Immunohistochemical and tissue culture studies of two cases.

Authors:  T Sano; K Kovacs; S L Asa; H S Smyth
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 7.  Molecular determinants of pituitary cytodifferentiation.

Authors:  S L Asa; S Ezzat
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

Review 8.  Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife.

Authors:  Jay Jagannathan; Chun-Po Yen; Nader Pouratian; Edward R Laws; Jason P Sheehan
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

9.  Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy.

Authors:  I A Felix; E Horvath; K Kovacs; H S Smyth; D W Killinger; J Vale
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

10.  Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.

Authors:  M C Vantyghem; C Cortet; C Bauters; M H Gevaert; D Dewailly; J Lefebvre; M Mazzucca
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.